(Circulation. 2006;114:2382-2389.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
From the Departments of Radiology (H.P., T.M., A.H.M., Z.Z., W.S.) and Neurosurgery (G.A.H.) and the Cardiovascular Research Center (H.P., T.M., Z.Z., W.S.), University of Virginia, Charlottesville, and Interdepartmental Program in Vascular Biology and Transplantation, Boyer Center for Molecular Medicine and Department of Surgery (Y.W., G.T.), Yale University School of Medicine, New Haven, Conn.
Correspondence to Weibin Shi, University of Virginia, MR4 Room 1171, Box 801339, 409 Lane Rd, Charlottesville, VA 22908. E-mail ws4v{at}virginia.edu
Received May 16, 2006; revision received August 14, 2006; accepted September 22, 2006.
| Abstract |
|---|
|
|
|---|
Methods and Results Thoracic aortic segments from 8-week-old female B6 and C3H apolipoprotein Edeficient mice were transplanted into the infrarenal aorta of 10-week-old female F1 mice. After transplantation, recipients were maintained on a chow diet for 16 weeks. The donor aortic segments of B6 mice developed significantly larger atherosclerotic lesions than those of C3H (44 983±11 702 versus 5600±4885 µm2 per section; P=0.011). Expression of vascular cell adhesion molecule (VCAM)-1 by endothelial cells was examined both in vitro and in vivo. B6 mice expressed significantly more VCAM-1 than their C3H counterparts. Sequence analysis of VCAM-1 cDNA revealed a nucleotide difference in the coding region that resulted in substitution of an amino acid in the protein product.
Conclusions These data provide direct proof that factors operating in the vessel wall, particularly endothelial cells, can serve as atherosclerosis modifiers and suggest a possibility for the contribution of VCAM-1 to atherosclerosis susceptibility.
Key Words: atherosclerosis endothelium grafting transplantation
| Introduction |
|---|
|
|
|---|
Clinical Perspective p 2389
The availability of numerous mouse strains that differ in susceptibility to atherosclerosis provides an experimental method for identifying the role of various cellular components in atherogenesis. C57BL/6 (B6) and C3H/HeJ (C3H) mice are 2 commonly used inbred strains that differ strikingly in the development of atherosclerosis when fed an atherogenic diet2 or when deficient in apoE (apoE/).3 Previous studies have revealed various differences between B6 and C3H in atherogenic processes involving vascular wall cells. Indeed, B6 mice exhibit a significant increase in apoB-containing lipoproteins in the arterial wall compared with C3H mice when fed an atherogenic diet or when deficient in apoE.4 In response to OxLDL, endothelial cells and smooth muscle cells from B6 mice express significantly more MCP-1, M-CSF, and VCAM-1 than cells from C3H mice.5,6 Moreover, endothelial responses to OxLDL cosegregate with the size of atherosclerotic lesions, as observed in a set of recombinant inbred strains derived from strains B6 and C3H.3 Direct evidence for the contribution of arterial walls to atherosclerosis susceptibility is still missing, however.
Aorta transplantation in the mouse provides a direct means for studying the role of the vascular wall in a biological process in vivo. This technique was initially described by Koulack et al,7 who transplanted a segment of thoracic aorta into the infrarenal aorta of a recipient mouse. Although the aorta transplantation procedure is used primarily to study long-term graft rejection, it also is used to investigate the progression or regression of atherosclerotic lesions in apoE/ mice.8,9 Grafting from parental to F1 strains avoids allogeneic rejection responses; thus, in the present study, we performed aorta transplantation to determine atherosclerotic lesion formation of aortic grafts from B6 and C3H mice in their F1 hybrids. Previously, we observed a 7-fold difference in VCAM-1 mRNA levels at the baseline in endothelial cells of B6 and C3H mice.3 Because VCAM-1 is an adhesion molecule that functions to recruit monocytes, the present study also tested the hypothesis that VCAM-1 contributes to the variation in atherosclerosis susceptibility of the 2 strains.
| Methods |
|---|
|
|
|---|
Aorta Transplantation Procedure
The aorta transplantation procedure in the mice was performed as described by Reis et al.8 Briefly, both donors and recipients were anesthetized with ketamine/xylazine, 60 to 80/5 to 10 mg/kg, by intramuscular injection. For donor operation, once appropriate sedation was achieved, the anterior chest wall, lungs, and esophagus were removed under sterile conditions. The aorta was flushed thoroughly with phosphate-buffered saline containing 5 U/mL heparin through the left ventricle of the heart. Descending thoracic aorta was dissected out from surrounding tissues, transected, and kept in ice-cold saline before use. Aortic segments (
5 mm in length) from 1 donor mouse were serially transplanted into 3 recipients. For recipient operation, a midline abdominal incision was made, and the viscera was retracted outside the abdominal cavity with a moist cotton swab. Then the aorta and vena cava were exposed and separated from each other, and 2 microvascular clamps were placed on the infrarenal abdominal aorta. The aorta between the clamps was transected with microvascular scissors, and the prepared aortic graft was anastomosed end to end with the recipient aorta with a total of 6 to 8 sutures for each anastomosis. After completion of the anastomosis, the distal clamp was removed, followed by the proximal clamp. The intestines were returned to the abdominal cavity, the abdominal musculature and the skin were closed in 2 layers, and 1 mL saline was injected into the peritoneal cavity. After the procedure, mice were maintained on a regular rodent chow diet for 16 weeks.
Tissue Preparation and Lesion Quantification
Sixteen weeks after the vascular transplantation procedure, recipient mice (5 to 9 mice in each group) were euthanized by cervical dislocation after isoflurane anesthesia. The aorta was perfused with 4% paraformaldehyde via the left ventricle of the heart. The donor aortic graft, together with adjacent recipient aorta, was dissected out and embedded in optical coherence tomography compound. In a separate group, the infrarenal aorta of 30-week-old female B6.apoE/ (n=4) and C3H.apoE/ (n=6) mice without undergoing aorta transplantation was harvested to assess atherosclerotic lesions. Serial 10-µm-thick cryosections were collected and mounted on poly-D-lysinecoated slides. Sections were stained with oil red O and hematoxylin and counterstained with fast green, and the lesion areas were counted by light microscopy.
Immunohistochemical Analysis
The presence of macrophages, T lymphocytes, dendritic cells, and endothelial cells in aortic grafts was determined by staining with antibodies to mouse MOMA-2 (Accurate Chemicals, Westbury, NY), CD3, or CD11c (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) or to the von Willebrand factor (Sigma-Aldrich, St Louis, Mo) as previously described.11 Briefly, frozen sections were fixed with acetone, followed by incubation with the primary antibodies. After a thorough wash, the sections were incubated with biotinylated secondary antibodies (Vector Laboratories, Burlingame, Calif). The reactions were visualized with peroxidase chromogen kits (Vector Laboratories).
Plasma Lipid Analysis
Mice were fasted overnight before being killed, and blood was collected by retro-orbital venous plexus puncture with the animals under isoflurane anesthesia. Plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were determined with the Thermo DMA (Louisville, Colo) cholesterol and triglyceride kits, which were adapted for a microplate assay.12 Briefly, 6 µL plasma samples, lipid standards, and controls were loaded in a 96-well plate and then mixed with 150 µL cholesterol or triglyceride reagents. After a 5-minute incubation at 37°C, the absorbance at 500 nm was read on a Molecular Devices (Menlo Park, Calif) plate reader. HDL cholesterol levels were determined after precipitation of very-low-density lipoprotein and LDL cholesterol fractions with a precipitating reagent provided by the company.
Lipoprotein Isolation and Modification
LDL (density, 1.019 to 1.069 g/mL) was isolated from the serum of healthy human donors by density-gradient ultracentrifugation as previously described by Havel et al,13 dialyzed in phosphate-buffered saline containing 0.3 mmol/L ethylenediaminetetraacetic acid (EDTA), filtered through 0.22-µm filters, and stored at 4°C. Lipoprotein concentrations were expressed as protein content. OxLDL was prepared by incubating LDL at a concentration of 5 mg/mL with 7 µmol/L FeSO4.5
Detection of VCAM-1 on Endothelial Cells
Endothelial cells were isolated from the thoracic aorta of female wild-type B6 and C3H mice by an established explantation technique.5 Briefly, the aortic segments were placed on Matrigel and incubated in Dulbeccos modified Eagles medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 90 µg/mL heparin, 60 µg/mL endothelial cell growth supplements, and 100U/mL fungizone. The vessel segments were removed once cell outgrowth was observed. The cells were passaged with Dispase and then plated into gelatin-coated culture dishes. The subsequent passages were performed with 0.25% trypsin-EDTA. At passage 4, cells were plated in 96-well tissue culture plates and allowed to grow to confluence. Confluent cells were incubated overnight in Dulbeccos modified Eagles medium containing 1% fetal bovine serum before being treated with medium containing 100 µg/mL Fe2+-modified LDL and 2 µg/mL lipopolysaccharide (LPS). After 4 hours of incubation, the medium was removed, and the cells were fixed with 1% paraformaldehyde in phosphate-buffered saline. VCAM-1 on endothelial cells was determined by enzyme-linked immunosorbent assay (ELISA). Briefly, endothelial cells were washed and incubated with 100 µL rat anti-mouse VCAM-1 antibody (1:250 dilution, BD Pharmingen, San Diego, Calif) per well for 45 minutes at 37°C. Cell monolayers were then washed and incubated with a biotinylated rabbit anti-rat IgG (1:200 dilution) for 45 minutes. After washing, cells were incubated with avidin-alkaline phosphatase for 45 minutes. Substrate was then applied to wells for 30 minutes. The absorbance was measured at 550 nm.
Western Blot Analysis for VCAM-1
Expression of VCAM-1 in the aortic wall of 8-week-old apoE/ mice fed a chow diet was determined by Western blot analysis. Aorta protein was prepared as we previously described.14 Briefly, the aorta was washed thoroughly with phosphate-buffered saline containing 5 U/mL heparin and 1 mmol/L EDTA through the heart, cleaned of periadventitial fat and connective tissues, and snap-frozen in liquid nitrogen. The frozen aorta was mechanically broken up; dispersed in lysis buffer containing 10 mmol/L Tris, pH 8, 1 mmol/L EDTA, 2.5% sodium dodecyl sulfate, and 5% mercaptoethanol; and centrifuged at 500g for 10 minutes at 4°C. The supernatant was collected and used for detection of VCAM-1. Aorta protein (10 µg) was separated by electrophoresis on 4% to 12% Tris polyacrylamide gels and electrophoretically transferred onto polyvinyl difluoride membranes (Invitrogen, Carlsbad, Calif). The membranes were incubated with a primary antibody against mouse VCAM-1 (BD Pharmingen) overnight and then incubated for 0.5 hour with an alkaline phosphataseconjugated secondary antibody. Signals were detected by the chemiluminescence method (Invitrogen).
Measurements of Soluble VCAM-1
Mice were fasted overnight before blood was collected through retro-orbital veins under isoflurane anesthesia. An ELISA kit for soluble mouse VCAM-1 assay was purchased from R&D Systems (Minneapolis, Minn), and the assays were performed by following the manufacturers instructions.
Sequence Analysis of VCAM-1
Total RNA was isolated from endothelial cells of B6 and C3H mice, and cDNA was prepared by use of the Superscript reverse transcription polymerase chain reaction kit (Invitrogen). The cDNA of VCAM-1 was analyzed by sequencing in both directions. The polymerase chain reaction primers used for sequencing were as follows: 5'-G A C T T C A G C C C A G A A A G C A G-3'/5'-C C A C G T G G A T A C T T C G T T C C-3'; 5'-A G T C C G T T C T G A C C A T G G A G-3'/5'-G G T C A T T G T C A C A G C A C C A C-3'; 5'-C C C G T C A T T G A G G A T A T T G G-3'/5'-C C A T T G A G G G G A C T G T C T G T-3'; 5'-G G T T G T T C T G A C G T G T G C T G-3'/5'-C T C T G C C T C T G T T T G G G T T C-3'; 5'-T T T G G A A A C G A C C T T C A T C C-3'/5'-A C G A G C C A T C C A C A G A C T T T-3'; and 5'-G T G C C C G A A A C A T G G A T A A T-3'/5'-A C T T C A A C G A T G G G G A C T T G-3'. We also sequenced the promoter region of the VCAM1 gene from polymerase chain reactionamplified genomic DNA using these primers: 5'-C A T G C C T T T G A G T C C T T T C C-3'/5'-A T C C A G G G A T G A C A T T-3'; 5'-T C C A C T C A C T T G G G T G A G A A C-3'/5'-A A A A T C T A G A A G A G A A A C G T T C A A A-3'; 5'-G C C T T T G T C C A A T G A C A T G A-3'/5'-T G G A T T T C T T T G G C T G C A T T-3'; 5'-G A C A T G G G C T A T G C A T G C A T G T G T-3'/5'-G T G T G T G T G A C A G C A A A G A C A G-3'; and 5-T C A T G A T A A T G G G T C A A T A A A A C A-3'/5'-C C A T C T T C A C A G G C A T T T C A-3'.
Statistical Analysis
All values are expressed as mean±SEM, with n indicating the number of mice. Student t test was used to determine the statistical differences between the 2 strains in all measurements. Differences were considered statistically significant at P<0.05.
The authors had full access to the data and take responsibility for their integrity. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
|
Immunohistochemical analysis revealed the presence of numerous macrophage foam cells in the lesions of both B6 and C3H grafts (Figure 3). Scattered T lymphocytes and dendritic cells were observed in the lesions of B6 grafts. In both grafts, a thin layer of endothelial cells lining the inner surface of the vessel was detected.
|
Differential VCAM-1 Expression on Endothelial Cells
Expression of VCAM-1 on endothelial cells derived from wild-type B6 and C3H mice after treatment with medium, OxLDL, and LPS for 4 hours was analyzed by ELISA (Figure 4). The baseline VCAM-1 level was significantly higher in B6 than in C3H cells (optical density, 0.77±0.11 versus 0.13±0.01; P=0.021; n=3 for each strain). Moreover, both OxLDL and LPS significantly increased VCAM-1 expression on endothelial cells of B6 mice (P<0.05). In contrast, VCAM-1 on C3H endothelial cells was not significantly induced by OxLDL or LPS (P>0.05).
|
Differential VCAM-1 Expression in Aortic Walls
To determine whether differences in VCAM-1 expression could be detected in vivo, protein was prepared from the aorta of 8-week-old B6.apoE/ and C3H.apoE/ mice on a chow diet and analyzed by Western blot analysis. As shown in Figure 5, VCAM-1 protein had 2 different forms: the full-length long form and the truncated form. The long form has a molecular weight of 110 kDa; the short form has a molecular weight of 47 kDa.15 The expression of VCAM-1 in aortic walls was lower in C3H than in B6 mice for both of the forms, but the reduction was more dramatic for the truncated form in C3H.
|
Soluble VCAM-1 Levels in Plasma
Soluble VCAM-1 levels in plasma of 8-week-old B6.apoE/ and C3H.apoE/ mice on the chow diet were measured by ELISA (Figure 6). Plasma VCAM-1 levels were significantly higher in B6.apoE/ mice than in C3H.apoE/ mice (671±42 versus 451±17 ng/mL; P=0.0018; n=6 for each strain).
|
Sequence Variation Between B6 and C3H VCAM-1 cDNA
Nucleotide sequences in both promoter and coding regions of the VCAM1 gene were analyzed for B6 and C3H mice. A single base-pair change (A2077G) was identified within the coding region at 2077 bp from A of the start codon (ATG), which results in amino acid substitution (Figure 7A). The amino acid change occurred at residue 693, where B6 has an asparagine and C3H has an aspartic acid. Within the promoter region of the VCAM1 gene, a nucleotide change at 243 bp upstream of the start code ATG was located (C-243A) (Figure 7B).
|
| Discussion |
|---|
|
|
|---|
We took advantage of the apoE/ mouse model to investigate atherosclerosis development of transplanted aortic grafts in a hyperlipidemic environment. ApoE/ mice represent a mouse model in which spontaneous hyperlipidemia and atherosclerosis occur even on a chow diet.10,16 Moreover, these mice develop all phases of atherosclerotic lesions seen in humans in large and medial arteries in a time-dependent manner.17 In contrast, the diet-induced mouse model of atherosclerosis develops only small fatty streak lesions that are largely limited to the aortic root, even after being fed the Paigen diet for 14 weeks to 9 months.18 In this study, donor aortic grafts were obtained from 8-week-old apoE/ mice. At this stage, both strains are known to have no detectable atherosclerotic lesions in the aorta.3,17 Thus, the difference between the donor aortas in lesion formation was not associated with differences in preexisting lesions. F1 hybrids between B6.apoE/ and C3H.apoE/ mice were used as recipients for aortic grafts, thus avoiding allogeneic rejection as a contributing factor for lesion formation. Studies of male grafts to female recipients would be confounded by rejection across minor histocompatibility antigens encoded by genes on the Y chromosome. In addition, the present results may not be extrapolated to male mice because they were not studied.
There are a 100-fold difference in the size of atherosclerotic lesions at the aortic root3 and a 40-fold difference in the infrarenal aorta (Figure 3) between B6.apoE/ and C3H.apoE/ mice on the chow diet. In the present study, however, we observed only a >10-fold difference in the lesion size of transplanted aortas from the 2 donors. One explanation for the discrepant result is that systemic factors also contribute to the difference in atherosclerosis susceptibility of the 2 strains.
Transplanted aortas developed much larger atherosclerotic lesions compared with those that were not transplanted, suggesting that the transplantation procedure had resulted in aggravated lesion formation. Recently, we have compared the 2 strains in lesion formation after arterial injury and found that B6.apoE/ mice are more responsive to arterial injury than C3H with regard to lesion sizes.11 Thus, the difference between aortic grafts of the 2 strains in lesion formation in the F1 recipients could be partially attributable to a differential response to injury that occurred during the transplantation procedure.
In the present study, we observed a marked difference between B6 and C3H mice in VCAM-1 expression by endothelial cells both at baseline and after stimulation with OxLDL and LPS. The endothelial cells of B6 mice expressed significantly more VCAM-1 protein than the cells of C3H mice. Moreover, we demonstrated a dramatic reduction in VCAM-1 expression in the aortic wall of C3H mice compared with B6 mice in vivo. In mice, VCAM-1 exists in 2 forms: the long form and the truncated form. Moy et al19 first cloned the truncated form of mouse VCAM-1 cDNA resulting from alternative splicing of the VCAMl gene and characterized the truncated VCAM-1 as a fully functional adhesion molecule. Shortly thereafter, Kumar et al15 cloned and characterized the mouse Vcam1 gene, mapped the gene to chromosome 3, and further characterized the truncated VCAM-1. Both long and truncated forms of VCAM-1 are found to be inducible in multiple tissues with stimulation of endotoxin. We previously have observed that both forms of VCAM-1 mRNA are induced by OxLDL in endothelial cells of B6 but not C3H mice.3 In this study, we found that both forms of VCAM-1 were reduced in C3H, but the reduction was more dramatic for the truncated form. VCAM-1 is a member of the immunoglobulin superfamily known to be expressed by endothelial cells for recruitment of leukocytes during inflammation.20 VCAM-1 interacts with the integrin
4ß1 (very-late-acting antigen 4), which is constitutively expressed on the surface of leukocytes. Blockade of the VCAM-1/very-late-acting antigen 4 pathway reduces monocyte adhesion and infiltration,21,22 and disruption of VCAM-1 domain 4 reduces monocyte migration and inhibits atherosclerotic lesion formation in apoE/ and LDL receptordeficient mice.23,24 A lower expression of this proinflammatory molecule by endothelial cells is expected to lead to fewer monocytes being recruited to the subendothelial space where they differentiate, take up lipids, and form foam cells. Thus, the difference in VCAM-1 expression by endothelial cells is likely to contribute to the difference between B6 and C3H mice in atherosclerosis susceptibility.
Interestingly, we observed a significant reduction in plasma soluble VCAM-1 levels in C3H mice. This lower plasma level of soluble VCAM-1 appears to reflect the lower expression of VCAM-1 in the arterial wall. Indeed, although the origins of circulating adhesion molecules have not been clarified, these soluble forms are most likely derived from shedding or proteolytic cleavage from endothelial cells on which these molecules are originally expressed.25
Although the expression level of VCAM-1 is likely to contribute to the variation in atherosclerosis susceptibility, its structural differences also may contribute. Sequence analysis of B6 and C3H VCAM-1 cDNA revealed 1 amino acid difference between the 2 strains at residue 693, with B6 having asparagine and C3H having aspartic acid. We also identified a nucleotide substitution in the promoter region of the VCAM1 gene, which was likely to contribute to the variation in VCAM-1 expression. The amino acid substitution could potentially influence the function of VCAM-1.
The demonstration that the difference in atherosclerosis susceptibility between mouse strains B6 and C3H are due, at least in part, to genetic differences in the arterial wall provides the first direct proof that genetic factors in atherosclerosis act at the level of vessel walls, although there is a possibility that an influence from other components has been made on the arterial wall before transplantation that could affect subsequent atherosclerosis in the new environment. This study also suggests that variations of VCAM-1 expression and structure may contribute to the resistance of C3H mice to atherosclerosis.
| Acknowledgments |
|---|
This work was supported by National Institutes of Health grants HL071844, NIH HL075433, and NIH HL070295; the Partners Fund Award from the Cardiovascular Research Center; and the Deans R&D award from the University of Virginia, School of Medicine.
Disclosures
None.
| References |
|---|
|
|
|---|
1 defined components, it would represent a major advance in the search for genes influencing atherosclerosis. Inbred mouse strains C57BL/6J (B6) and C3H/HeJ (C3H) exhibit marked differences in atherosclerosis susceptibility. This study determined whether the difference in atherosclerosis susceptibility resides at the level of arterial walls. Thoracic aortic segments from B6 and C3H apolipoprotein Edeficient mice were transplanted into the infrarenal aorta of F1 mice. After transplantation, recipients were maintained on a chow diet for 16 weeks. The donor aortic segments of B6 mice developed significantly larger atherosclerotic lesions than those of C3H. This study provides the first direct proof that factors operating in the vessel wall can serve as atherosclerosis modifiers.
| Footnotes |
|---|
This article has been cited by other articles:
![]() |
Q. Li, Y. Li, Z. Zhang, T. R. Gilbert, A. H. Matsumoto, S. E. Dobrin, and W. Shi Quantitative Trait Locus Analysis of Carotid Atherosclerosis in an Intercross Between C57BL/6 and C3H Apolipoprotein E-Deficient Mice Stroke, January 1, 2008; 39(1): 166 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Wang, W. Shi, X. Wang, L. Velky, S. Greenlee, M. T. Wang, T. A. Drake, and A. J. Lusis Mapping, Genetic Isolation, and Characterization of Genetic Loci That Determine Resistance to Atherosclerosis in C3H Mice Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2671 - 2676. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Schwartz, Z. S. Galis, M. E. Rosenfeld, and E. Falk Plaque Rupture in Humans and Mice Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 705 - 713. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |